Xenia Hotels & Resorts (XHR) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for May 13, 2025, with proposals including director elections, a say-on-pay vote, an amendment to the 2015 Incentive Award Plan, and ratification of KPMG LLP as auditor for 2025.
The company reported a 1.7% increase in RevPAR, a 2.3% increase in occupancy, and a 1.8% decrease in ADR for 2024.
Major capital projects included the sale of Lorien Hotel & Spa, a new $825M credit facility, a $400M senior note issuance, and significant renovations, especially at Grand Hyatt Scottsdale Resort.
Over $64M was returned to shareholders via dividends and share repurchases in 2024.
As of year-end, liquidity stood at $568M, with no debt maturities until March 2026.
Voting matters and shareholder proposals
Shareholders will vote on electing eight directors, approving executive compensation (say-on-pay), amending the 2015 Incentive Award Plan to add 2,250,000 shares, and ratifying KPMG LLP as auditor.
The board recommends voting FOR all proposals.
Proxy access and majority voting standards are in place, and shareholders can amend bylaws.
Board of directors and corporate governance
The board consists of eight members, seven of whom are independent, with diverse backgrounds in real estate, finance, governance, and sustainability.
Annual board and committee self-evaluations, executive sessions, and robust succession planning are conducted.
Stock ownership guidelines, anti-hedging/pledging, and a clawback policy are enforced.
The board regularly engages with investors, reaching out to holders of over 56% of shares in 2024.
Latest events from Xenia Hotels & Resorts
- Double-digit earnings growth in 2025 with strong demand; 2026 outlook remains positive.XHR
Q4 202514 Mar 2026 - Net income up, EBITDAre down, and guidance trimmed as renovations and expense pressures persist.XHR
Q2 20242 Feb 2026 - Q3 loss and margin pressure offset by occupancy gains, strong group demand, and project completions.XHR
Q3 202415 Jan 2026 - 2025 guidance projects 3.5–6.5% RevPAR growth and $244–$264M Adjusted EBITDAre.XHR
Q4 202423 Dec 2025 - Board recommends approval of all proposals, including director elections and plan amendment.XHR
Proxy Filing2 Dec 2025 - Board seeks approval to expand equity awards, reinforcing pay-for-performance alignment.XHR
Proxy Filing2 Dec 2025 - Q1 2025 net income and RevPAR surged, but guidance was trimmed amid macro uncertainty.XHR
Q1 202528 Nov 2025 - Q2 net income soared over 259% on asset sale and group demand, with raised full-year guidance.XHR
Q2 202516 Nov 2025 - Year-to-date net income and EBITDAre rose despite a Q3 net loss and flat RevPAR.XHR
Q3 20252 Nov 2025